CSL Vifor, the U.S. subsidiary of Australian pharmaceutical company CSL, will lay off 55 employees reporting to its primary office in King of Prussia, Pennsylvania, effective December 1, 2025. The layoffs were announced through a Worker Adjustment and Retraining Notification (WARN) Act notice recently filed with state authorities. According to company statements, the decision follows a comprehensive evaluation of business needs and the shifting economic environment.
These job cuts primarily affect the company's medical affairs and commercial operations teams. The move is part of CSL’s previously disclosed strategy to reduce its global workforce by up to 15%, which could impact approximately 4,350 jobs worldwide. The restructuring aims to generate annual cost savings of $500–$550 million over the next three years and includes merging commercial and medical functions of CSL Vifor and CSL Behring in an effort to increase operational synergies.
CSL acquired Vifor Pharma in late 2021 in an $11.7 billion deal to expand its presence in nephrology and iron deficiency markets. The current layoffs reflect the company’s ongoing efforts to streamline its global structure and respond to commercial and regulatory challenges.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!